Date of Degree
PhD (Doctor of Philosophy)
Steven M. Varga
First Committee Member
John D Colgan
Second Committee Member
Kevin L Legge
Third Committee Member
Jon C Houtman
Fourth Committee Member
John T Harty
Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis-induced hospitalization in young children. A natural RSV infection fails to elicit long-lasting immunity, further increasing the need for an effective vaccine. Despite the significant healthcare burden, there is no licensed RSV vaccine currently available. While most RSV vaccine strategies focus on the induction of humoral immunity, high antibody titers do not prevent RSV infection. It remains unclear if protective immunity can be achieved through robust cellular immunity. Previous work has indicated that a relatively low frequency of virus-specific CD8 T cells is induced following an RSV infection in human infants. In addition, RSV-specific memory CD8 T cells diminish to almost undetectable frequencies in the blood of the elderly. The lack of long-lasting immunity against RSV may be explained by an absence or low frequency of memory CD8 T cells within the lung following infection. However, I determined that the majority of effector CD8 T cells reside within the lung tissue following infection with either RSV or influenza A virus (IAV), both of which replicate primarily in the airways. In addition, approximately 70% of antigen-experienced memory CD8 T cells persist in the lung tissue at day 30 following RSV infection. In contrast, the majority of CD8 T cells remain in the pulmonary vasculature following intranasal infection with either of the systemically replicating viruses lymphocytic choriomeningitis virus or vaccinia virus. Therefore, the tissue tropism of a virus will determine if CD8 T cells preferentially accumulate in the lung tissue following infection of the respiratory tract.
An experimental formalin-inactivated RSV (FI-RSV) vaccine caused enhanced respiratory disease in vaccinated children following a natural RSV infection. Incomplete knowledge of the underlying immunological mechanisms that were responsible for mediating the enhanced disease has greatly hampered vaccine development. Previous studies have indicated that eosinophils, non-neutralizing antibodies, and CD4 T cells may be required to elicit FI-RSV vaccine-enhanced disease. I determined that distinct CD4 T cell subsets mediate individual disease parameters. The Th2-biased immune response, but not eosinophils specifically, was responsible for induction of airway hyperresponsiveness and mucus hypersecretion. On the other hand, the Th1-associated pro-inflammatory cytokine TNF-α was required to mediate baseline pulmonary dysfunction and weight loss. Lastly, while depletion of CD4 T cells ameliorated all disease parameters evaluated, the antibody titers remained unaltered in depleted mice. Thus, antibodies induced by FI-RSV immunization were not required for vaccine-enhanced disease. My data demonstrate that discrete disease manifestations associated with FI-RSV immunization are orchestrated by distinct subsets of CD4 T cells.
The CD8 T cell response is believed to contribute to both pathogen clearance and immunopathology following an acute RSV infection. However, it is unclear if robust memory CD8 T cell responses will protect against an RSV infection. I determined that induction of a high-magnitude, epitope-specific memory CD8 T cell pool mediated increased viral clearance following RSV challenge. However, mice with robust secondary CD8 T cell responses exhibit increased airway dysfunction, weight loss, and mortality as compared to mock-immunized mice undergoing an acute RSV infection. The enhanced disease severity was unique to the context of an RSV infection as similarly immunized mice were protected from chge with a lethal dose of a recombinant IAV engineered to express an RSV-derived epitope. In addition, the increased morbidity and mortality was associated with an elevated amount of both IFN-γ and TNF-α in the serum of immunized mice. Neutralization of either IFN-γ or TNF-α led to a significant reduction in disease severity and survival of all mice. These results demonstrate that robust memory CD8 T cell responses enhance viral clearance, but also lead to severe pulmonary immunopathology following RSV infection. Overall, I establish that the majority of effector CD8 T cells are localized within the lung tissue following a respiratory infection, and determine that either memory CD4 or CD8 T cell responses elicits severe immunopathology following a RSV infection.
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in young children. There is no vaccine available despite the significant healthcare burden. In addition, individuals remain susceptible to re-infection throughout their life. During the 1960's, children administered an inactivated RSV vaccine candidate experienced greater disease following a natural RSV infection, requiring approximately 80% of children to be hospitalized in one study as compared to 5% in the control group. The lack of understanding as to what caused the vaccine-enhanced disease has severely hampered RSV vaccine development. My work investigates how vaccination with the inactivated vaccine altered the immune response following RSV infection. I demonstrate that a particular subset of immune cells, CD4 T cells, is responsible for the RSV-enhanced disease observed in vaccinated individuals.
In addition to CD4 T cells, CD8 T cells are also important for eliminating RSV following infection. However, CD8 T cells have also been implicated in mediating disease following infection. Therefore, I questioned if robust CD8 T cell responses could be utilized to protect against RSV infection. I determined that while large CD8 T cell responses accelerate viral clearance, the CD8 T cells also cause excessive lung damage. Collectively, my work defines the impact of eliciting robust memory T cell responses following an RSV infection and will help define critical parameters for future vaccine development.
publicabstract, Intravascular staining, Lung, Respiratory syncytial virus, T cell, Vaccine-enhanced disease
xiii, 175 pages
Includes bibliographical references (pages 150-175).
Copyright 2015 Cory Knudson